124 related articles for article (PubMed ID: 35409016)
1. Factors Affecting the Stability of Platinum(II) Complexes with 1,2,4-Triazolo[1,5-
Jakubowski M; Łakomska I; Kaszuba A; Wojtczak A; Sitkowski J; Jarzęcki AA
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409016
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic malonate platinum(II) complexes with 1,2,4-triazolo[1,5-a]pyrimidine derivatives: structural characterization and mechanism of the suppression of tumor cell growth.
Łakomska I; Hoffmann K; Wojtczak A; Sitkowski J; Maj E; Wietrzyk J
J Inorg Biochem; 2014 Dec; 141():188-197. PubMed ID: 25277461
[TBL] [Abstract][Full Text] [Related]
3. Platinum(II) Complexes with Bulky Disubstitute Triazolopyrimidines as Promising Materials for Anticancer Agents.
Łakomska I; Śmiłowicz D; Jakubowski M; Sitkowski J; Wojtczak A
Materials (Basel); 2020 Nov; 13(23):. PubMed ID: 33255252
[TBL] [Abstract][Full Text] [Related]
4. Nanoencapsulation of a ruthenium(ii) complex with triazolopyrimidine in liposomes as a tool for improving its anticancer activity against melanoma cell lines.
Fandzloch M; Jaromin A; Zaremba-Czogalla M; Wojtczak A; Lewińska A; Sitkowski J; Wiśniewska J; Łakomska I; Gubernator J
Dalton Trans; 2020 Jan; 49(4):1207-1219. PubMed ID: 31903475
[TBL] [Abstract][Full Text] [Related]
5. Multinuclear NMR spectroscopy and antitumor activity of novel platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines.
Łakomska I; Szłyk E; Sitkowski J; Kozerski L; Wietrzyk J; Pełczyńska M; Nasulewicz A; Opolski A
J Inorg Biochem; 2004 Jan; 98(1):167-72. PubMed ID: 14659646
[TBL] [Abstract][Full Text] [Related]
6. Rational design of dicarboxylato platinum(II) complexes with purine-mimetic ligands as novel anticancer agents.
Hoffmann K; Wiśniewska J; Wojtczak A; Sitkowski J; Denslow A; Wietrzyk J; Jakubowski M; Łakomska I
J Inorg Biochem; 2017 Jul; 172():34-45. PubMed ID: 28477537
[TBL] [Abstract][Full Text] [Related]
7. Platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo [1,5-a]pyrimidines: spectroscopical characterization and cytotoxic activity in vitro.
Łakomska I; Fandzloch M; Popławska B; Sitkowski J
Spectrochim Acta A Mol Biomol Spectrosc; 2012 Jun; 91():126-9. PubMed ID: 22366623
[TBL] [Abstract][Full Text] [Related]
8. Mono- and dinuclear platinum(II) compounds with 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine. Structure, cytotoxic activity and reaction with 5'-GMP.
Łakomska I; Kooijman H; Spek AL; Shen WZ; Reedijk J
Dalton Trans; 2009 Dec; (48):10736-41. PubMed ID: 20023903
[TBL] [Abstract][Full Text] [Related]
9. First dinuclear rhodium(II) complexes with triazolopyrimidines and the prospect of their potential biological use.
Fandzloch M; Augustyniak AW; Dobrzańska L; Jędrzejewski T; Sitkowski J; Wypij M; Golińska P
J Inorg Biochem; 2020 Sep; 210():111072. PubMed ID: 32563102
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization, crystal structures and in vitro antistaphylococcal activity of organotin(IV) derivatives with 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidine.
Girasolo MA; Canfora L; Sabatino P; Schillaci D; Foresti E; Rubino S; Ruisi G; Stocco G
J Inorg Biochem; 2012 Jan; 106(1):156-63. PubMed ID: 22119808
[TBL] [Abstract][Full Text] [Related]
11. Structure-cytotoxicity relationship for different types of mononuclear platinum(II) complexes with 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine.
Łakomska I; Fandzloch M; Muzioł T; Sitkowski J; Wietrzyk J
J Inorg Biochem; 2012 Oct; 115():100-5. PubMed ID: 22926029
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties.
Fandzloch M; Dobrzańska L; Jędrzejewski T; Jezierska J; Wiśniewska J; Łakomska I
J Biol Inorg Chem; 2020 Feb; 25(1):109-124. PubMed ID: 31741123
[TBL] [Abstract][Full Text] [Related]
13. Sawhorse-type ruthenium complexes with triazolopyrimidine ligands - what do they represent in terms of cytotoxic and CORM compounds?
Fandzloch M; Jędrzejewski T; Wiśniewska J; Sitkowski J; Dobrzańska L; Brożyna AA; Wrotek S
Dalton Trans; 2022 Jun; 51(22):8804-8820. PubMed ID: 35616922
[TBL] [Abstract][Full Text] [Related]
14. Palladium(II) and platinum(II) organometallic complexes with 4,7-dihydro-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine. Antitumor activity of the platinum compounds.
Ruiz J; Villa MD; Cutillas N; López G; de Haro C; Bautista D; Moreno V; Valencia L
Inorg Chem; 2008 Jun; 47(11):4490-505. PubMed ID: 18447329
[TBL] [Abstract][Full Text] [Related]
15. A New Synthesis of Poly Heterocyclic Compounds Containing [1,2,4]triazolo and [1,2,3,4]tetrazolo Moieties and their DFT Study as Expected Anti-cancer Reagents.
Abdelrehim EM; El-Sayed DS
Curr Org Synth; 2020; 17(3):211-223. PubMed ID: 32101129
[TBL] [Abstract][Full Text] [Related]
16. Differentiation between [1,2,4]triazolo[1,5-a] pyrimidine and [1,2,4]triazolo[4,3-a]-pyrimidine regioisomers by 1H-15N HMBC experiments.
Salgado A; Varela C; García Collazo AM; Pevarello P
Magn Reson Chem; 2010 Aug; 48(8):614-22. PubMed ID: 20589727
[TBL] [Abstract][Full Text] [Related]
17. New annelated thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines, with potent anticancer activity, designed through VLAK protocol.
Lauria A; Abbate I; Patella C; Martorana A; Dattolo G; Almerico AM
Eur J Med Chem; 2013 Apr; 62():416-24. PubMed ID: 23395722
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin.
Bakalova AG; Buyukliev RT; Nikolova RP; Shivachev BL; Mihaylova RA; Konstantinov SM
Anticancer Agents Med Chem; 2019; 19(10):1243-1252. PubMed ID: 30767754
[TBL] [Abstract][Full Text] [Related]
19. Kinetics and mechanism for reversible chloride transfer between mercury(II) and square-planar platinum(II) chloro ammine, aqua, and sulfoxide complexes. Stabilities, spectra, and reactivities of transient metal-metal bonded platinum-mercury adducts.
Gröning O; Sargeson AM; Deeth RJ; Elding LI
Inorg Chem; 2000 Sep; 39(19):4286-94. PubMed ID: 11196924
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
